Network-Based Identification of Genetic Effect of SARS-CoV-2 Infections on Idiopathic Pulmonary Fibrosis Patients

    September 2020 in “ Briefings in Bioinformatics ”
    Tasnimul Alam Taz, Kawsar Ahmed, Bikash Kumar Paul, Md Kawsar, Nargis Aktar, Sakib Mahmud, Mohammad Ali Moni
    TLDR SARS-CoV-2 may worsen IPF due to shared genes and pathways, suggesting potential drug targets.
    The study investigated the genetic effects of SARS-CoV-2 on idiopathic pulmonary fibrosis (IPF) patients using bioinformatics tools to analyze gene expression data. It identified 11 common differentially expressed genes (DEGs) between COVID-19 and IPF, including SAA2, MMP9, and ICAM1, and highlighted five hub genes with significant interactions in protein-protein interaction networks. The research suggested that SARS-CoV-2 might worsen IPF by affecting specific genetic pathways and identified potential drug candidates, such as parthenolide and miglitol, for treating both conditions. The study emphasized the importance of considering genetic factors in managing COVID-19 in individuals with pre-existing pulmonary conditions, although it acknowledged limitations due to the small sample size and the novelty of SARS-CoV-2.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results